Gilead Sciences Inc. stocks have been trading up by 3.5 percent after promising HIV therapy trial results boosted investor confidence.
Click Here for a Millionaire's POV on Trading GILD
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- FDA cleared Trodelvy for first-line treatment of advanced triple-negative breast cancer, alone or with Merck’s Keytruda, with NCCN naming it a category 1 preferred option.
- European regulators granted first-line Trodelvy monotherapy approval across the EU and EEA, with a Keytruda combo filing under review for PD-L1–positive patients.
- HSBC upgraded Gilead Sciences (GILD) to Buy with a higher $155 target, while the broader Street sits around $160.78 and leans Buy-rated.
- GILD’s once-weekly ISL/LEN HIV regimen hit key Phase 3 endpoints with clean safety, reinforcing the long-acting HIV strategy that HSBC cites as underappreciated.
- An upcoming July 9 non-Hodgkin lymphoma call will keep attention on Gilead’s hematologic oncology presence alongside its solid tumor advances.
Live Update At 10:02:30 EDT: On Tuesday, July 07, 2026 Gilead Sciences Inc. stock [NASDAQ: GILD] is trending up by 3.5%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
Gilead Sciences, ticker GILD, has quietly been grinding higher on the chart. Over the past few weeks, GILD climbed from the mid-$120s to a recent close around $134.25, with a strong push on 2026/07/07 after the latest bullish headlines. The intraday 5‑minute action shows an early spike from about $132.60 at the open to a high near $135.67, then a controlled fade that still held most of the gains. That’s classic “gap, push, and hold” behavior, not a blow‑off top.
More Breaking News
- Arista Networks Stock Rallies As Wall Street Chases AI Switch Boom
- TE Stock Slides As Losses Collide With Tight Chart Range
- Redwire RDW Stock Slumps After 17.5% Single-Day Drop
- Ford Stock Holds Range As Quality Gains Offset Sales Drop
Under the hood, GILD throws off serious cash. Quarterly revenue sits near $6.96B, with gross margins around 79.4% and an EBIT margin close to 39.5%. Profitability is strong, and return on equity above 25% tells traders this management team knows how to turn capital into earnings. Free cash flow of roughly $2.43B in the latest quarter supports ongoing dividends (about 2.5% yield) and buybacks. Debt is meaningful, but a current ratio of 2.0 and interest coverage around 14.4x keep the balance sheet in a comfortable zone. At a price/earnings ratio near 17.8 and price/sales about 5.5, GILD trades like a mature pharma name, but the recent oncology and HIV catalysts give that multiple room to stretch if growth accelerates.
Why Traders Are Watching GILD Now
For active traders, GILD just shifted from slow‑and‑steady value name to a genuine catalyst stock. The big trigger is Trodelvy. The FDA signed off on Trodelvy as a first-line treatment for unresectable or metastatic triple‑negative breast cancer, both as monotherapy in patients who can’t take PD‑(L)1 drugs and in combo with Merck’s Keytruda for PD‑L1–positive tumors. On top of that, NCCN guidelines now list Trodelvy, with or without Keytruda, as a category 1 preferred first‑line option regardless of PD‑L1 status. That language matters. It basically tells U.S. oncologists this is a go‑to regimen, not a niche add‑on.
At the same time, Europe is opening up. The European Commission granted first‑line monotherapy approval for Trodelvy in similar advanced TNBC patients across all EU states and the EEA, and regulators are reviewing a supplemental filing to pair Trodelvy with Keytruda for PD‑L1–positive disease. If that combo clears, Gilead Sciences would mirror its U.S. positioning and turn Trodelvy into a backbone therapy on both sides of the Atlantic.
Layer in the analyst angle. HSBC just upgraded GILD to Buy, bumping its target from $133 to $155 and arguing the market is too negative on HIV after generic pressure. FactSet data showing a Buy‑leaning Street and an average target near $160.78 backs that up. Add the positive Phase 3 readout for the weekly ISL/LEN HIV combo, and you get a narrative that GILD’s legacy HIV cash cow has more life left, right as oncology starts to inflect. That mix of fresh drug approvals, pipeline wins, and target hikes is exactly what momentum traders hunt for.
Conclusion
GILD is no tiny biotech lotto ticket. It’s a $B‑scale pharma name with deep revenues, but the tape is starting to trade like a catalyst story again. The Trodelvy first‑line approvals in the U.S. and Europe reshape the drug’s commercial runway and support the idea that Gilead Sciences is building a real oncology growth engine, not just a side hustle to HIV. The Keytruda partnership locks GILD into one of the strongest brands in immuno‑oncology, which usually helps with physician adoption and combo pricing power.
On the HIV side, the successful Phase 3 ISL/LEN data lines up neatly with HSBC’s call that long‑acting regimens can offset generic pressure. That’s important, because traders watching GILD’s valuation need to see durable HIV cash flows while oncology ramps. With strong free cash flow, a solid dividend, and analyst targets well above the current price, the setup gives active traders something to game around catalysts like further European combo decisions and the upcoming lymphoma landscape call.
As Tim Sykes likes to remind traders, “patterns repeat because human nature doesn’t change — your job is to recognize the pattern and manage your risk.” As Tim Bohen, lead trainer with StocksToTrade says, “Time and experience have taught me that missed opportunities are part of the game. There’s always another setup around the corner.” For GILD, the pattern right now is a big‑cap name coming off a period of pessimism just as fundamentals start to improve. The opportunity is there, but the same rules apply: plan your trade, size smart, and cut losses fast.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.